Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin

Anti-Cancer Drugs

Volumn 8, Issue 2, 1997, Pages 189-198

  Masanek, Ulrike ^a   Stammler, Gerd ^a   Volm, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell lines; Co expression; Glutathione peroxidase; Glutathione S transferase ; Ovarian carcinoma,; P glycoprotein; Protein kinase C; Proto oncogenes; Thymidylate synthase

Indexed keywords

CISPLATIN; COLCHICINE; DNA; DOXORUBICIN; GLUTATHIONE PEROXIDASE; GLYCOPROTEIN P; HISTONE H3; ISOENZYME; MESSENGER RNA; PACLITAXEL; PROTEIN KINASE C; THYMIDYLATE SYNTHASE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL SUBPOPULATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ONCOGENE C JUN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031047490     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199702000-00010     Document Type: Article

References (51)

1. Einhorn N. Treatment of ovarian cancer: the state of the art. Med Oncol Tumor Pharmacother 1993; 10: 139-42.
2. Bradley G, Juranca PF, Ling V Mechanism of multidrug resistance. Biochim Biophys Acta 1988; 948: 87-128.
3. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-61.
4. Doroshow JH, Akman S, Chu F-F, Esworthy S. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol Ther 1990; 47: 359-70.
5. Dusre L, Mimnaugh EG, Myers CE, Sinha BK. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 1989; 49: 511-5.
6. Akman SA, Forrest G, Chu FF, Esworthy RS, Doroshow JH. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 1990; 50: 1397-402.
7. Hofmann GA, Mattern MR. Topoisomerase II in multiple drug resistance. Cytotechnology 1993; 12: 137-54
8. Scanlon KJ, Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci. USA 1988; 85: 650-3.
9. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmacol Ther 1991; 52: 385-406.
10. Ritke MK, Bergoltz VV, Allan WP, Yalowich JC. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 1994; 48: 525-33.
11. Yamazaki H, Schneider E, Meyers CE, Sinha BK. Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochim Biophys Acta 1994; 1226: 89-96.
12. Bhushan A, Abramson R, Chiu J-F, Tritton TR. Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharmacol 1992; 42: 69-74.
13. Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M, Scanlon KJ. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul 1992;32: 195-209.
14. Angel P, Karin M. The role of JUN, FOS and AP-1 complex in cell-proliferation and transformation. Biochim Biopbys Acta 1991; 1072: 129-57.
15. Chaudhary PM, Roninson IB. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists Oncol Res 1992; 4: 281-90.
16. Yu G, Ahmad S, Aquino A, Fairchild CR. Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein Cancer Commun 1991; 3: 181-9.
17. Carpenter G, Zendegui JG. Epidermal growth factor, its receptor, and related proteins. Exp Cell Res 1986; 164: 1-10.
18. Christen RD, Hom DK, Porter DC, et al. Epidermal growth factor receptor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990; 86: 1632-40.
19. Rowinsky EK, Onetto N, Canetta RM. Arbuck SC. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646-62.
20. Van der Zee AGJ, Hollema HH. De Bruijn HWA, et al. Cell biological markers of drug resistance in ovarian carcinoma, Gynecol Oncol 1995; 58: 165-78.
21. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991; 266: 3987-94.
22. Cowan NJ, Dobner PR, Fuchs EU, Clereland DW. Expression of human alpha-tubulin genes: interspecies conservation of 3′ untranslated regions. Mol Cell Biol 1983; 3: 1738-45.
23. Hall JL, Dudley L, Dohner PR, Lewis SA, Cowan NJ. Identification of two human beta-tubulin isotypes. Mol Cell Biol 1983; 3: 854-62.
24. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-rcsistant human lung cancer cell line. Science 1992; 258: 1650-4.
25. Merlino GT, Ishii S, Whang-Peng J, et al. Structure and localisation of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 1985; 5: 1722-34.
26. Kano T, Sakai M, Muramatsu M. Structure and expression of a human class pi giutathione S-transferase messenger RNA. Cancer Res 1987; 47: 5626-30.
27. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
28. Tsai-Pflugfelder M, Liu LFF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome 17q21-22. Proc Natl Sci USA 1988; 85: 7177 81.
29. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNA: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984; 12: 1687-96.
30. Van Straaten F, Mueller R, Curran T, Van Beveren C, Verma JM. Complete nucleotide sequence of a human c-oncogene: deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci USA 1983; 80: 3183-7.
31. Finkenzeller G, Marme D, Hug H. Sequence of humen protein kinase C alpha. Nucleic Acids Res 1990; 18: 2183-3.
32. Kubo K, Ohno S, Suzuki K. Primary structures of human protein kinase C beta I and beta II differ only in their C-terminal sequences. FEBS Lett 1987; 223: 138-42.
33. Tokunaga K, Nakamura Y, Sakata K, et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 1987; 47: 5616-9.
34. Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase π in resistant non-small cell lung carcinoma of smokers. Br J Cancer 1989; 64: 700-4.
35. Volm M, Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non-small cell king carcinomas. Anticancer Res 1992; 12: 2293-6.
36. Volm M, Efferth T, Günther A, Lathan B. Detection of murine S 180 cells expressing a multiclrug resistance phenotype using different in vitro test systems and monoclonal antibodys. Arzneim-Forsch/Drug Res 1987; 37: 862-7.
37. Dumontet C, Duran GE, Steger A, Beketic-Oreskovic L, Sikic BI. Resistance mechanismus in human sarcoma mutants derived by single-step exposure to Paclitaxel (Taxol). Cancer Res 1996; 56: 1091-7.
38. Chao CC-K, Huang Y-T, Ma CM, Chou W-Y, Lin-Chao S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug resistant human colon cancer cell line. Mol Pharmacol 1992; 41: 69-75.
39. Samuels BL, Murray JL, Cohen MB, et al. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 1991; 51: 521-7.
40. Benchekroun MN, Pourquier P, Schott B, Robert J. Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 1993; 211: 141-6.
41. Wang Y, Teicher BA, Shea TC, et al. Cross-resistance and glutathione S-transferase-π levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res 1989; 49: 6185-92.
42. Chu E, Drake JC, Koeller DM, et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39: 136-43.
43. Volm M, Kästel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase π, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993; 71: 3981-7.
44. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986; 25: 2248-56.
45. Volm M, Koomägi R, Mattern J. Prognostic significance of proliferating cell nuclear antigen (PCNA) in adenocarcinoma of the lung. Int J Oncol 1995; 6: 359-62.
46. Stammler G, Sauerbrey A, Volm M. Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblasic leukemia. Cancer Letters 1995; 89: 129-35.
47. Ohta S, Nishio K, Kubota N, et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 1994; 85: 290-7.
48. Ohta S, Nishio K, Kubo S, et al. Characterization of a vindesine-resistant human small-cell lung cancer cell line. Br J Cancer 1993; 68: 74-9.
49. Slapac CA, Rubin EH, Kufe DW. Constitutive c-jun overexpression in doxorubicin and vincristine selected, multidrug-resistant U937 cells. Proc Am Ass Cancer Res 1993; 34: A1874.
50. Ibrado AM, Ponnathpur V, Reed J, et al. Protein kinase C and tyrosine kinase activities affect taxol induced apoptosis in human leukemic cells. Proc Am Ass Cancer Res 1994; 35: A1868.
51. Chao CK, Ma CM, Cheng P-W, Lin-Chao S. Increased mdr gene expression and decreased drug accumulation in a human colonic cancer cell line resistant to hydrophobic drugs. Biochem Biophys Res Commun 1990; 172: 842-9.